Connect with us

Health

Some cancer patients could avoid surgery with innovative new therapy

Published

on

Some cancer patients could avoid surgery with innovative new therapy

NEWYou can now listen to Fox News articles!

An experimental drug has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

BCG (Bacillus Calmette-Guérin) is an immunotherapy drug that is often the first-line treatment for certain early-stage bladder cancers.

The new drug, TAR-200 — which was evaluated in a trial sponsored and conducted by Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson — may offer a less invasive alternative to bladder removal surgery.

KILLER CONDITION LANDS IN TOP 10 LEADING CAUSES OF DEATH AS GLOBAL CASES SURGE

Advertisement

TAR-200 is a small, drug-releasing device placed directly into the bladder through a simple outpatient procedure, without general anesthesia, according to the study press release. 

Once inserted, it slowly releases the chemotherapy drug gemcitabine over several weeks.

Researchers say the new bladder-inserted device could spare patients from losing their bladder entirely. (iStock)

“Traditionally, these patients have had very limited treatment options. This new therapy is the most effective one reported to date for the most common form of bladder cancer,” said study lead Sia Daneshmand, M.D., director of urologic oncology with Keck Medicine of USC, in a press release. 

“The findings of the clinical trial are a breakthrough in how certain types of bladder cancer might be treated, leading to improved outcomes and saved lives.”

Advertisement

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Bladder cancer is the fourth most common cancer in men and the 11th most common cancer in women.

According to the Urology Care Foundation, non-muscle-invasive bladder cancer is found in the tissue that lines the inner surface of the bladder. 

“Bladder cancer is one of the 10 most common cancers worldwide, yet treatment options have remained largely unchanged for over 40 years.”

High-risk NMIBC carries a greater chance of coming back after treatment. This study aimed to find an option for patients whose cancer recurred even after standard therapy.

Advertisement

“The standard treatment plan for these patients was surgery to remove the bladder and surrounding tissue and organs, which has many health risks and may negatively impact patients’ quality of life,” said Daneshmand.

This new therapy could eventually allow some patients to avoid that procedure.

Trial results showed that many patients stayed cancer-free for more than two years. (iStock)

All participants in the study had high-risk NMIBC that did not respond to the standard immunotherapy drug BCG. The study was split into multiple groups who tested different combinations of drugs and treatment methods.

In one group, patients received TAR-200 once every three weeks for about six months, followed by maintenance treatments every 12 weeks for up to two years.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Among 85 patients in this group, 82.4% showed no detectable signs of cancer after treatment. In that group, 52.9% remained cancer-free at one year, and many stayed cancer-free for more than two years without needing additional therapy.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

In another group of patients with a less aggressive type of early-stage bladder cancer, early disease-free survival rates were 85.3% at six months and 81.1% at nine months. Overall, 94% were able to keep their bladders.

The clinical trial results were published earlier this year in the Journal of Clinical Oncology.

Advertisement

The TAR-200 device delivers gemcitabine directly to the bladder, keeping the drug where it’s needed most. (iStock)

The researchers emphasized that this is still mid-stage (Phase 2b) data. Longer-term, larger trials and regulatory reviews are still needed before the treatment could become standard care. 

“Because the study didn’t include a traditional comparison (no randomized control arm), we can’t definitively say how TAR-200 stacks up against other treatments in a fair head-to-head way,” the researchers wrote. 

CLICK HERE FOR MORE HEALTH STORIES

Patients in this study are a specific subset (BCG-unresponsive and eligible for bladder preservation) and may not represent all bladder-cancer cases.

Advertisement

“Also, follow-up time remains relatively short and the number of patients modest, meaning we don’t yet know how long the benefits will last or how they apply to larger, more diverse groups of people,” the researchers added.

Health

Male fertility rates crash as doctors reveal health threats: ‘Something very wrong’

Published

on

Male fertility rates crash as doctors reveal health threats: ‘Something very wrong’

NEWYou can now listen to Fox News articles!

Scientists and physicians agree that there’s been a general decline in male fertility — but they aren’t sure why.

Social media buzz has pointed to a few environmental exposures as potential factors, including cellphones and electric vehicles.

But the reality is “more complicated” than that, according to experts who recently spoke to National Geographic.

ORIGIN OF DEADLY CANCER AFFECTING YOUNG ADULTS REVEALED IN ALARMING REPORT

Advertisement

Although it’s not clear whether the decline is at a stage where it should be considered a crisis, numbers show that overall fertility — demographically measured by the number of babies born compared to women of child-bearing age — has decreased.

Scientists and physicians agree that there’s been a general decline in male fertility. (iStock)

Dr. Alex Robles of the Columbia University Fertility Center in New York confirmed that clinical practitioners are “certainly seeing more couples where the male factor contributes to infertility.”

CELLPHONE HEALTH RISKS IN FOCUS OF NEW GOVERNMENT STUDY: ‘VERY CONCERNED’

“At least one-third of couples we evaluate have some male component,” he told Fox News Digital.

Advertisement

A 2017 meta-analysis published in Oxford Journals: Human Reproduction Update found that sperm counts in Western countries have declined by almost 60% globally since 1973. The 2023 update confirmed these same results.

Urologists can track declining fertility in sperm quality, while demographic data uses the number of babies born compared to women of child-bearing age as a benchmark, according to National Geographic. (iStock)

Lead study author and epidemiologist Hagai Levine warned that this trend could lead to human extinction if it isn’t addressed.

“This is the canary in the coal mine,” Levine, public health physician at the Hebrew University-Hadassah Braun School of Public Health, told National Geographic. “It signifies that something is very wrong with our current environment, as lower sperm counts predict morbidity and mortality.”   

DOCTORS WARN SOME POPULAR FOODS AND DRINKS COULD BE SECRETLY SABOTAGING MEN’S TESTOSTERONE LEVELS

Advertisement

These findings have been contradicted by other studies, however. A 2025 Cleveland Clinic analysis of studies from the last 53 years found sperm counts to be steady.

“There is no evidence to suggest that this decline is the cause of a precipitous decline in the ability to cause pregnancies,” primary study author Scott Lundy, a reproductive urologist at Cleveland Clinic, told National Geographic. “Most men, even with a modest decline in sperm counts, will still have no issues conceiving.”

Potential factors of decline

Multiple lifestyle factors can lead to a decline in male fertility, Robles noted, including obesity, smoking and diet, as well as environmental exposures and delayed parenthood.

National Geographic also reported that heavy drinking and marijuana use directly contribute to declining fertility and that quitting these habits, while also exercising and losing weight, can help.

Smoking of any kind can contribute to a decline in fertility, according to experts. (iStock)

Advertisement

Systemic inflammation, infection and disease can also have a “big, profound effect on the current status of fertility,” Lundy told National Geographic. 

Those who are getting over a fever from an infection, like the flu or COVID, will have a “drastically lower” sperm count for three months, he said.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Male infertility can also be a marker of overall health, according to Robles. “Poor semen parameters are associated with other medical conditions and may signal underlying metabolic, hormonal or environmental issues,” he told Fox News Digital.

Experts recommend seeing a doctor to discuss fertility concerns instead of relying on the internet. (iStock)

Advertisement

Allan Pacey, deputy dean of the Faculty of Biology, Medicine and Health at the University of Manchester, told National Geographic that the decline could be caused by increased use of contraception, as well as men waiting longer to have children or choosing not to have them at all.

CLICK HERE FOR MORE HEALTH STORIES

Microplastics have also been raised on social media as a potential culprit, but the effects are unclear, according to experts.

There is some evidence of endocrine-disrupting chemicals — which are substances found in reusable plastics and some disposable products — altering male fertility, Lundy revealed to National Geographic.

Myths busted

Concerns have circulated on social media that keeping a cellphone in a front pocket could harm male fertility. While Lundy said such an effect is biologically possible, there is currently no scientific evidence supporting the claim.

Advertisement

Another common myth is that infertility is mostly a women’s issue, Robles noted, but male factors contribute to about one-third to one-half of all cases.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The claim that taking supplements can boost sperm counts is another common myth, he said, adding that it’s not backed by strong scientific evidence.

“Men should focus on factors that we know matter: maintaining a healthy weight, avoiding tobacco, limiting alcohol and managing chronic health conditions,” Robles advised. 

One common myth is that infertility is mostly a women’s issue, but male factors contribute to about one-third to one-half of all cases. (iStock)

Advertisement

Experts recommend seeing a urologist to address fertility concerns. Robles said his approach begins with an evaluation, semen analysis, hormonal testing and medical history, while also exploring lifestyle factors.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

In addition to traditional treatment options, Robles said his fertility center also uses advanced tools that incorporate AI and robotics.

“Technologies like this are expanding options for patients who previously had very limited paths to biological parenthood,” he said.

Advertisement
Continue Reading

Health

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier

Published

on

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier


Advertisement





How To Curb Late-Night Cravings and Make Weight Loss Easier | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

Published

on

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

NEWYou can now listen to Fox News articles!

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.

Advertisement

That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.

The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release. 

KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS

The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.

After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia. 

Advertisement

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge. (iStock)

Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital. 

“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”

“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.

Advertisement

This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.

A specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk. (iStock)

“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.

This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.

Advertisement

The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release. 

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” a researcher said. (iStock)

“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Advertisement

Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

More research is needed before this approach can be considered for clinical use prior to cognitive symptoms. 

Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”

Continue Reading

Trending